Hytest

Product Catalog

2025

Introduction

OVER 30 YEARS OF REALIZING SUCCESS THROUGH SCIENCE AND COMMITMENT

Since 1994, we have developed and supplied immunological reagents for the IVD industry and research community. Nowadays, we provide products for several clinical and research areas and are proud to be a leading provider of reagents for troponin I immunoassays, as well as for certain infectious diseases.

QUALITY – FROM DEVELOPMENT TO DELIVERIES

We are renowned for uncompromised quality that extends from product development to safe and secure deliveries worldwide. Continuous investment in scientific research forms a solid foundation for our product development and our ISO 9001 certified operations ensure that our products meet the highest levels of quality that you expect.

WORLD CLASS SERVICE

We aim to provide excellent customer service for our industrial and research customers. Our dedicated Tech Support team is ready to answer your questions and additional information about our products is available on our website. Our Technotes will guide you in more detail about product features and best pair recommendations for your applications.

In order to serve our customers on a global level, we have had a subsidiary in China operating since 2011 and a subsidiary in the United States since 2024. We are continuing to develop and expand our team in North America so that we can improve the operations and provide an even better local service to our customers.

SCIENTIFIC EXCELLENCE FOR IVD

At Hytest, we have a complete understanding of the needs of both our industrial partners and the research community. This is why we are able to help our customers achieve success. And this explains why most of the major diagnostics companies rely on Hytest's ability to supply the best reagents in the world.

STARTING A NEW PROJECT? YOU CAN SAVE UP TO 50%*

Don't forget about our evaluation samples opportunity. This is the option to test an antibody at a special price before purchasing a larger quantity, which gives you more freedom in your projects. Get more details by contacting customer service at **hytest@hytest.fi**.

see page 7

ABBREVIATIONS USED IN THE CATALOG

a.a.r. Amino acid residue
A/C Affinity chromatography
C/r Cross-reactivity, cross-reaction
EIA Enzyme immunoassay
FITC Fluorescent isothiocyanate
FSH Follicle stimulating hormone
HCG Human chorionic gonadotropin
HIT Haemagglutinin inhibition test
HK2 Human kallikrein 2
ID Immunodiffusion
IF Immunofluorescence
IHC Immunohistochemistry
IP Immunoprecipitation
LH Luteinizing hormone
LPS Lipopolysaccharide
MAb Monoclonal antibody
MW Molecular weight
N/A Not applicable
N/cr No cross-reaction
PCT Procalcitonin
PLA Plaque-linked assay
proMB Proform of eosinophil major basic protein
RIA Radioimmunoassay
TSH Thyroid stimulating hormone
VN Virus neutralization
WB Western blotting

***Terms:** The special offer opportunity is only available to end users. Institutes and universities are not included in this promotion. The usual shipping and handling costs will still apply. The opportunity is a one-time evaluation possibility, feedback about the evaluation results is expected and you can get more details by contacting Hytest customer service at **hytest@hytest.fi**.*

Troponin I (TnI)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Troponin I cardiac	4T21cc	M18cc	IgG1	*In vitro*, EIA, WB, a.a.r. 18-28
		1017cc	IgG1	*In vitro*, EIA, WB, a.a.r. 22-40
		1039cc	IgG1	*In vitro*, EIA, WB, a.a.r. 22-40
		4C2cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 23-29
		M155cc	IgG1	*In vitro*, EIA, WB, a.a.r. 26-35
		19C7cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 41-49
		560cc	IgG1	*In vitro*, EIA, WB, a.a.r. 83-93
		Y101	IgG1	*In vitro*, EIA, a.a.r. 83-100
		16A11cc	IgG1	*In vitro*, EIA, WB, a.a.r. 86-90
		16A12cc	IgG1	*In vitro*, EIA, WB, a.a.r. 86-90
		8E10cc	IgG1	*In vitro*, EIA, WB, a.a.r. 86-90
		MF4cc	IgG1	*In vitro*, EIA, WB, a.a.r. 190-196
	4T21	P4-14G5	IgG1	EIA, WB, a.a.r. 1-15
		916	IgG3	EIA, WB, a.a.r. 13-22
		909	IgG1	EIA, WB, a.a.r. 18-22
		801	IgG3	EIA, WB, a.a.r. 18-35
		810	IgG1	EIA, WB, a.a.r. 22-31
		3C7	IgG1	EIA, WB, a.a.r. 25-40
		228	IgG1	EIA, WB, a.a.r. 26-35
		820	IgG1	EIA, WB, a.a.r. 26-35
		10F4	IgG2a	EIA, WB, a.a.r. 34-37
		247	IgG1	a.a.r. 65-74, only free cTnI
		17F3	IgG1	EIA, WB, a.a.r. 87-90
		84	IgG1	EIA, WB, a.a.r. 117-126
		M46	IgG1	EIA, WB, a.a.r. 130-145, <10 % C/r with skeletal troponin I
		625	IgG1	EIA, WB, a.a.r. 169-178
		458	IgM	EIA, WB, a.a.r. 169-178
		596	IgG1	EIA, WB, a.a.r. 169-178, <10 % C/r with skeletal troponin I
		267	IgG2a	EIA, WB, a.a.r. 169-178, <10 % C/r with skeletal troponin I
		C5	IgG2b	EIA, WB, a.a.r. 186-192, >50 % C/r with skeletal troponin I
		p45-10	IgG1	EIA, WB, a.a.r. 195-209
	RC4T21	RecChim19C7	IgG1	EIA, recombinant chimeric antibody
		RecChim16A11	IgG1	EIA, recombinant chimeric antibody
		RC560	IgG1	EIA, recombinant chimeric antibody
		Y306	IgG	EIA, a.a.r. 22-40, recombinant rabbit antibody
		Y503	IgG1	EIA, a.a.r. 22-40, recombinant chimeric antibody
		RecR1	IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody
		RecR23	IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody
		RecR33	IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody
		RecR85	IgG	EIA, a.a.r. 24-40, recombinant rabbit antibody
		Y303	IgG	EIA, a.a.r. 28-34, recombinant rabbit antibody
		Y309	IgG	EIA, a.a.r. 39-54, recombinant rabbit antibody
		Y302	IgG	EIA, a.a.r. 83-100, recombinant rabbit antibody
		Y501	IgG1	EIA, a.a.r. 161-178, recombinant chimeric antibody
		Y504	IgG1	EIA, a.a.r. 161-178, recombinant chimeric antibody
		Y502	IgG1	EIA, a.a.r. 174-191, recombinant chimeric antibody
		Y505	IgG1	EIA, a.a.r. 174-191, recombinant chimeric antibody
		Y601	IgG1	EIA, a.a.r. 182-192, recombinant chimeric antibody
		Y603	IgG1	EIA, a.a.r. 182-192, recombinant chimeric antibody

Troponin I (TnI)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Troponin I cardiac, phosphorylated form	4T45	1G11	IgG2b	EIA, WB, a.a.r. N/A
Troponin I cardiac, dephosphorylated form	4T46	22B11	IgG2b	EIA, WB, a.a.r. 20-24
Troponin complex, cardiac	4TC2	20C6cc	IgG2b	*In vitro*, EIA
		Tcom8	IgG1	EIA
	RC4TC2	RecChim20C6	IgG1	EIA, recombinant chimeric antibody
Troponin I skeletal muscle	4T20	12F10	IgG2b	EIA, WB
		7G2	IgG2b	EIA, WB

POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Troponin I cardiac	4T21/2	goat	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
Troponin I cardiac, human	8T53	>98%	Human cardiac muscle
Troponin I cardiac, human, recombinant	8RTI7	>95%	Recombinant
Troponin I skeletal muscle, human	8T25	>95%	Human skeletal muscle
Troponin IC complex, cardiac, human, recombinant	8ICR3	>95%	Recombinant
Troponin I (fragment 28-110) – troponin C complex, cardiac, human, recombinant chimeric	8IFC20	>95%	Recombinant
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

DEPLETED SERUM

Product name	Cat. #	Source
Troponin I free serum	8TFS	Pooled normal human serum Currently provided wth Cat.# 8TFS2

Troponin T (TnT)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Troponin T cardiac	4T19cc	300cc	IgG1	*In vitro*, EIA, a.a.r. 119-138
		329cc	IgG1	*In vitro*, EIA, a.a.r. 119-138
		406cc	IgG2a	*In vitro*, EIA, a.a.r. 132-151
		1F11cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 145-164
		1C11cc	IgG1	*In vitro*, EIA, WB, a.a.r. 171-190
	4T19	9G6	IgG1	EIA, WB, a.a.r. 2-61
		7F4	IgG2b	EIA, WB, a.a.r. 67-86
		7G7	IgG1	EIA, WB, a.a.r. 67-86
		2F3	IgG2b	EIA, WB, a.a.r. 145-164
		1A11	IgG2b	EIA, WB, a.a.r. 145-164
		7E7	IgG1	EIA, WB, a.a.r. 223-242
	RC4T19	RecChim406	IgG1	EIA, recombinant chimeric antibody

ANTIGENS

Product name	Cat. #	Purity	Source
Troponin T cardiac, human, recombinant	8RTT5	>95%	Recombinant
Troponin T skeletal muscle, human	8T24	>95%	Human skeletal muscle
Troponin T fast skeletal, human, recombinant	8RFT4	>95%	Recombinant
Troponin T slow skeletal, human, recombinant	8RST2	>95%	Recombinant
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

Troponin C (TnC)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Troponin C	4T27cc	RC7B9	IgG1	EIA, recombinant chimeric antibody
		7B9cc	IgG1	*In vitro*, EIA, WB
Troponin complex, cardiac	4TC2	20C6cc	IgG2b	*In vitro*, EIA
		Tcom8	IgG1	EIA
	RC4TC2	RecChim20C6	IgG1	EIA, recombinant chimeric antibody

ANTIGENS

Product name	Cat. #	Purity	Source
Troponin C, human	8T57	>98%	Human cardiac muscle
Troponin C slow skeletal/cardiac, human, recombinant	8RSC4	>95%	Recombinant
Troponin C skeletal, isoform 2, human, recombinant	8RKC3	>90%	Recombinant
Troponin IC complex, cardiac, human, recombinant	8ICR3	>95%	Recombinant
Troponin I (fragment 28-110) – troponin C complex, cardiac, human, recombinant chimeric	8IFC20	>95%	Recombinant
Troponin ITC complex, cardiac, human, recombinant	8ITCR	>95%	Recombinant

ProBNP, BNP and NT-proBNP

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
BNP	4BNP2cc	429cc	IgG1	*In vitro*, EIA, a.a.r. 5-13
		100cc	IgG2a	*In vitro*, EIA, a.a.r. 10-15
		24C5cc	IgG1	*In vitro*, EIA, WB, a.a.r. 11-17
		130cc	IgG1	*In vitro*, EIA, a.a.r. 15-22
		50E1cc	IgG1	*In vitro*, EIA, WB, a.a.r. 26-32
		50B7cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 26-32
		57H3cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 26-32
	4BNP2	26E2	IgG1	EIA, WB, a.a.r. 11-22
Immune complex (24C5-BNP/proBNP)	4BFab5cc	Ab-BNP2cc	IgG2a	*In vitro*, EIA (only as pair with MAb 24C5cc, Cat.# 4BNP2cc)
	4BFab5	Ab-BNP4	IgG2a	EIA (only as pair with MAb 24C5cc, Cat.# 4BNP2cc)
NT-proBNP	4NT1cc	5B6cc	IgG1	*In vitro*, EIA, WB, a.a.r. 1-12
		29D12cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 5-12
		15F11cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 13-24
		13G12cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 15-20
		18H5cc	IgG1	*In vitro*, EIA, WB, a.a.r. 15-20
		7B5cc	IgG1	*In vitro*, EIA, WB, a.a.r. 15-21
		NT34cc	IgG1	*In vitro*, EIA, WB, a.a.r. 25-34
		NT13	IgG	EIA, LF, a.a.r. 27-31, recombinant rabbit antibody
		11D1cc	IgG1	*In vitro*, EIA, WB, a.a.r. 31-39
		16E6cc	IgG1	*In vitro*, EIA, WB, a.a.r. 34-39
		15C4cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 63-71
		NT45	IgG	EIA, LF, a.a.r 43-46, recombinant rabbit antibody
		NT46	IgG	EIA, LF, a.a.r 43-46, recombinant rabbit antibody
		24E11cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 67-76
	4NT1	16F3	IgG1	EIA, WB, a.a.r. 15-20
		15D7	IgG1	EIA, WB, a.a.r. 48-56
		28F8	IgG2a	EIA, WB, a.a.r. 67-76

ANTIGENS

Product name	Cat. #	Purity	Source
NT-proBNP, recombinant	8NT2	>95%	Recombinant
ProBNP, recombinant	8PRO9	>95%	Recombinant
ProBNP, glycosylated, recombinant	8GBP3	>95%	Recombinant

DEPLETED PLASMA

Product name	Cat. #	Source
BNP and NT-proBNP free plasma	8BFP	Pooled normal human plasma

Lipoprotein-associated phospholipase A2 (Lp-PLA2)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Lipoprotein-associated phospholipase A2	4LA7cc	PL4cc	IgG1	*In vitro*, EIA
		PL11cc	IgG1	*In vitro*, EIA
		PL26cc	IgG1	*In vitro*, EIA, WB
		PL42cc	IgG1	*In vitro*, EIA
		PL46cc	IgG1	*In vitro*, EIA

ANTIGEN

Product name	Cat. #	Purity	Source
Lipoprotein-associated phospholipase A2, recombinant	8PL7	>75%	Recombinant

Pregnancy-associated plasma protein-A (PAPP-A)

MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Dimeric form of pregnancy-associated plasma protein A (dPAPP-A), human	4PD4	PAPP30	IgG1	EIA, dimeric form of PAPP-A only

Myoglobin

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Myoglobin	4M23	4E2cc	IgG1	*In vitro*, EIA
		7C3cc	IgG1	*In vitro*, EIA
		1B4	IgG1	EIA

ANTIGEN

Product name	Cat. #	Purity	Source
Myoglobin	8M50	>95%	Human cardiac muscle

DEPLETED SERUM

Product name	Cat. #	Source
Myoglobin free serum	8MFS	Pooled normal human serum

Insulin-like growth factor binding protein 4 (IGFBP-4)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Insulin-like growth factor binding protein 4	4IGF4	IBP3cc	IgG3	*In vitro*, EIA
		IBP144	IgG2a	EIA
		IBP154	IgG2a	EIA
		IBP163	IgG1	EIA
		IBP180	IgG2a	EIA
		IBP182	IgG2b	EIA
		IBP185	IgG2b	EIA
		IBP190	IgG1	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
Insulin-like growth factor binding protein 4, N-terminal fragment (NT-IGFBP-4), human, recombinant	8NGP4	≥90%	Recombinant
Insulin-like growth factor binding protein 4, C-terminal fragment (CT-IGFBP-4), human, recombinant	8ILG4	≥90%	Recombinant

Fatty acid binding protein (FABP)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Fatty acid binding protein	4F29	5B5	IgG1	EIA
		9F3cc	IgG1	*In vitro*, EIA
		10E1	IgG1	EIA
		22	IgG1	EIA, WB
		25	IgG1	EIA
		28cc	IgG1	*In vitro*, EIA
		30	IgG1	EIA, WB
		31	IgG1	EIA, WB

ANTIGEN

Product name	Cat. #	Purity	Source
Fatty acid binding protein	8F65	>95%	Human cardiac muscle

DEPLETED SERUM

Product name	Cat. #	Source
Fatty acid binding protein free serum	8FFS	Pooled normal human serum

Myeloperoxidase (MPO)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Myeloperoxidase	4M43	4A4	IgG2b	EIA, WB
		18B7	IgG1	EIA, WB
		4B3	IgG1	EIA
		16E3	IgG1	EIA
		17G2	IgG2b	EIA
		19G8	IgG1	EIA

DEPLETED SERUM

Product name	Cat. #	Source
Myeloperoxidase free serum	8MPFS	Pooled normal human serum

C-reactive protein (CRP)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
C-reactive protein	4C28cc	C2cc	IgG1	*In vitro*, EIA, high sensitivity
		C4cc	IgG1	*In vitro*, EIA, Ca^{2+} dependent, high sensitivity
		C6cc	IgG2a	*In vitro*, EIA, high sensitivity
		CRP30cc	IgG1	*In vitro*, EIA, low affinity
		CRP135cc	IgG2b	*In vitro*, EIA, high sensitivity
	4C28	C1	IgG2b	EIA, WB , high sensitivity
		C3	IgG1	EIA, IHC, Ca^{2+} dependent, high sensitivity
		C5	IgG1	EIA, high sensitivity
		C7	IgG1	EIA, IHC, high sensitivity
		CRP11	IgG1	EIA, WB
		CRP36	IgG2a	EIA, WB, IHC
		CRP169	IgG2a	EIA, WB

ANTIGEN

Product name	Cat. #	Purity	Source
C-reactive protein (CRP), human, recombinant	8CR8	>95%	Recombinant

DEPLETED SERUM

Product name	Cat. #	Source
C-reactive protein free serum	8CFS	Pooled normal human serum

Soluble CD40 ligand (sCD40L)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Soluble CD40 ligand	4CD40	1H4	IgG1	EIA
		2A3	IgG1	EIA

Glycogen phosphorylase isoenzyme BB (GPBB)

MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Glycogen phosphorylase BB isoenzyme	4GP31	1G6	IgG2b	EIA, WB, BB isoenzyme

Soluble lectin-like oxidized LDL receptor (sLOX-1)

MONOCLONAL ANTIBODY

Product name	Cat. #	MAb	Isotype	Remarks
Soluble lectin-like oxidized LDL receptor	4LOX1	LOX19-22	IgG1	EIA, WB

ST2

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
ST2	4ST2	S985	IgG1	*In vitro*, FIA
		S101	IgG1	*In vitro*, FIA
		S103	IgG1	EIA, FIA, recombinant chimeric antibody
		S207	IgG	EIA, recombinant rabbit antibody
		S215	IgG	EIA, FIA, recombinant rabbit antibody
		S501	IgG1	EIA, FIA, recombinant chimeric antibody
		S512	IgG1	EIA, FIA, recombinant chimeric antibody

ANTIGEN

Product name	Cat. #	Purity	Source
ST2/ IL1RL1 protein, human, recombinant	8STR4	>95%	Recombinant

Blood Coagulation and Anemia

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
D-dimer	4D30	DD1	IgG2a	EIA, WB, N/cr with fibrinogen
		DD2	IgG2b	EIA, WB, N/cr with fibrinogen
		DD3cc	IgG2b	*In vitro*, EIA, WB, N/cr with fibrinogen
		DD4	IgG2b	EIA, WB, C/r with fibrinogen
		DD5	IgG2b	EIA, WB, C/r with fibrinogen
		DD6cc	IgG2a	*In vitro*, EIA, WB, C/r with fibrinogen
		DD22	IgG2a	EIA, WB, N/cr with fibrinogen
		DD41cc	IgG2a	*In vitro*, EIA, WB, N/cr with fibrinogen
		DD44cc	IgG2b	*In vitro*, EIA, WB, N/cr with fibrinogen
		DD46cc	IgG2a	*In vitro*, EIA, WB, N/cr with fibrinogen
		DD93	IgG1	EIA, WB, N/cr with fibrinogen
		DD189cc	IgG1	*In vitro*, EIA, WB, N/cr with fibrinogen
		DD255cc	IgG1	*In vitro*, EIA, WB, N/cr with fibrinogen
Erythropoetin	4ER1	Epo1	IgG1	EIA
		Epo2	IgG1	EIA
Ferritin	4F32	F23cc	IgG3	*In vitro*, EIA
		F31cc	IgG2b	*In vitro*, EIA
Fibrinogen	4F1	1F3	IgG2b	EIA, WB
		27C8	IgG2a	EIA, WB
		40F11	IgG2b	EIA, WB
Fibrinopeptide A	4FP1	1F7	IgG2a	EIA, WB
		49D2	IgG2a	EIA, WB
Transferrin	4T15	1C10cc	IgG1	*In vitro*, EIA
		8B9	IgG1	EIA, WB
		11D3	IgG1	EIA, WB
		12A6	IgG1	EIA, WB
Transferrin receptor	4Tr26cc	11F5cc	IgG2b	*In vitro*, EIA, WB
		13E4cc	IgG2a	*In vitro*, EIA, WB
	4Tr26	2B6	IgG2a	EIA, WB
		23D10	IgG2b	EIA, WB

ANTIGENS

Product name	Cat. #	Purity	Source
D-dimer	8D70	>90%	Human plasma
Transferrin receptor, soluble, recombinant	8ST6	>95%	Recombinant

Fertility and Pregnancy

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Alpha-fetoprotein (AFP)	4F16	5H7cc	IgG1	*In vitro*, EIA, WB
		4A3cc	IgG1	*In vitro*, EIA, WB
Anti-Müllerian hormone (AMH), human	4AM5	AMH41cc	IgG2a	*In vitro*, EIA, WB
		AMH46cc	IgG2a	*In vitro*, EIA, WB
		AMH47cc	IgG2a	*In vitro*, EIA, WB
		AMH60cc	IgG2b	*In vitro*, EIA, WB
		AMH65cc	IgG1	*In vitro*, EIA, WB
		AMH69cc	IgG2b	*In vitro*, EIA, WB
Human chorionic gonadotropin (HCG)	2H8	77F12	IgG2b	EIA, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH
		F1cc	IgG1	*In vitro*, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH
		27E8	IgG1	EIA, β-subunit, N/cr with LH, FSH, TSH
		28A4	IgG2a	EIA, β-subunit, N/cr with LH, FSH, TSH
Insulin-like growth factor binding protein-1 (IGFBP-1) (pp12)	4I52	G2	IgG2a	EIA, WB
Insulin-like growth factor binding protein-1 (IGFBP-1)	4IG8	G5F8	IgG1	EIA, WB
		C7B9	IgG1	EIA, WB
Pregnancy-associated plasma protein A (PAPP-A), human	4P41cc	10E1cc	IgG2b	*In vitro*, EIA, WB, PAPP-A subunit
		10E2cc	IgG2b	*In vitro*, EIA, PAPP-A subunit
	4P41	5H9	IgG2b	EIA, proMBP subunit
		4G11	IgG2a	EIA, WB, PAPP-A subunit
		3C8	IgG2a	EIA, WB, PAPP-A subunit
		10H9	IgG2a	EIA, PAPP-A subunit
		11E4	IgG2b	WB, proMBP subunit
		7A6	IgG2a	EIA, PAPP-A subunit
		PAPP52	IgG1	EIA, PAPP-A subunit

ANTIGEN

Product name	Cat. #	Purity	Source
Anti-Müllerian hormone (AMH), human, recombinant	8AM7	>90%	Recombinant
PAPP-A, human, recombinant	8PA1	>90%	Recombinant

Influenza A and B

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks	
Influenza A nucleoprotein	3IN5	FA17	IgG1	*In vitro*, EIA, LF, CLIA, WB	New!
		FA32	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		FA35	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		FA38	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		FA58	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		FA52	IgG1	EIA, LF, CLIA, WB, recombinant chimeric antibody	New!
		FA91	IgG1	EIA, LF, CLIA, WB, recombinant chimeric antibody	New!
		FA94	IgG1	EIA, LF, CLIA, WB, recombinant chimeric antibody	New!
		F8	IgG2a	EIA, IHC	
		InA108	IgG1	EIA, LF, WB	
		InA180	IgG3	EIA	
		InA224	IgG1	EIA, LF	
		InA245	IgG2b	EIA, LF, WB	
Influenza A haemagglutinin	3IH4	C102	IgG1	EIA, IF, HIT, IHC, haemagglutinin H1	
Influenza A haemagglutinin H1	3AH1	InA97	IgG1	EIA, WB	
		InA134	IgG1	EIA, WB	
		InA139	IgG1	EIA, WB	
Influenza A haemagglutinin H3	3HG3	InA227	IgG1	EIA, WB	
		InA246	IgG2a	EIA, WB	
Influenza A haemagglutinin H7	3HI7	InA331	IgG1	EIA	
		InA334	IgG1	EIA	
		InA414	IgG2b	EIA	
Influenza B group antigen	3IF18	IB44	IgG1	EIA, LF, CLIA, WB, recombinant chimeric antibody	New!
		IB57	IgG1	EIA, LF, CLIA, WB, recombinant chimeric antibody	New!
		IB70	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		IB71	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		IB87	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		IB91	IgG	EIA, LF, CLIA, WB, recombinant rabbit antibody	New!
		IB76	IgG1	*In vitro*, EIA, LF, CLIA, WB	New!
		InB12	IgG2b	EIA, WB, nucleoprotein	
		InB27	IgG1	EIA, WB, nucleoprotein	
		InB36	IgG1	EIA, WB, nucleoprotein	
		InB64	IgG1	EIA, WB, nucleoprotein	
		InB114	IgG1	EIA, WB, nucleoprotein	
		InB204	IgG1	EIA, WB, nucleoprotein	
		InB210	IgG1	EIA, WB, nucleoprotein	
		InB213	IgG1	EIA, WB, nucleoprotein	
Influenza B haemagglutinin	3BH9	InB18	IgG2a	EIA, WB, haemagglutinin 2 (HA2)	
		InB190	IgG2b	EIA, WB, haemagglutinin 2 (HA2)	
Influenza B matrix protein M1	3BM17	InB4	IgG1	EIA, WB	
	RIF17	R2/3	IgG2a	*In vitro*, EIA, WB, nucleoprotein	

SARS-CoV-2

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
SARS-CoV-2 Spike RBD	3CV2	R107	IgG1	*In vitro*, EIA, ACE2-RBD binding inhibition
		RBD1106	IgG1	EIA
SARS-CoV-2 Nucleoprotein	3CV4	C706	IgG	EIA, recombinant rabbit antibody
		C715	IgG	EIA, recombinant rabbit antibody
		C518	IgG1	*In vitro*, EIA
		C524	IgG1	*In vitro*, EIA
		C527	IgG1	*In vitro*, EIA

POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
SARS-CoV-2 Nucleoprotein	PSN5	goat	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
ACE2-Fc, human, recombinant	8AE5	>95%	Recombinant
SARS-CoV-2 Spike RBD, mammalian recombinant	8COV1	>95%	Recombinant
SARS-CoV-2 Nucleoprotein, recombinant	8COV3	>95%	Recombinant
SARS-CoV-2 Nucleoprotein fragment N47-A173, recombinant	8COV5	>95%	Recombinant

Other acute respiratory diseases (ARD)

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
Coxsackievirus B3	3CX3	PV25	IgG2a	EIA
Legionella pneumophila LPS	3L15	2F10	IgG3	EIA, C/r data available
		5F4RC	IgG3	EIA
Respiratory syncytial virus (RSV)	3ReS21cc	9C5cc	IgG2b	*In vitro*, EIA, WB, F protein
		8B10cc	IgG2a	*In vitro*, EIA, nucleoprotein

ANTIGENS

Product name	Cat. #	Purity	Source
Adenovirus, type 6	8AV13	>90%	Tonsil 99
Respiratory syncytial virus (RSV)	8RSV79	>90%	Strain Long

Foodborne pathogens

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
Caliciviridae (norovirus)	3CNV1	2A5	IgG2b	EIA, WB, HIT
		1B1	IgG2b	EIA, WB, HIT
Helicobacter pylori CagA-protein	3HE70cc	HP-1811cc	IgG3	*In vitro*, EIA, WB, IP, a.a.r. 562-795
Listeria monocytogenes	3L1	LZF7	IgG2a	EIA, WB
		LZH1	IgG1	EIA, WB
Rotavirus A	3R10	3C10cc	IgG2a	*In vitro*, EIA, IHC, WB, P42 antigen
Salmonella O-antigens	3SO22	10B10G	IgG3	A-group, C/r data available
Salmonella typhimurium	3S9	1E6cc	IgG1	*In vitro*, LPS of S. typhimurium

ANTIGEN

Product name	Cat. #	Purity	Source
Adenovirus, type 6	8AV13	>90%	Tonsil 99

Hepatitis

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Hepatitis B virus core antigen (HBcAg)	3HB17	H3A4cc	IgG2a	*In vitro*, EIA, WB
		H6F5	IgG2a	EIA, WB
Hepatitis B virus surface antigen (HBsAg)	3HB12	HB11	IgG1	EIA
		Hs33	IgG2a	EIA
		Hs41	IgG2a	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
HBsAg, ayw subtype, recombinant	8HS7ay	>98%	Recombinant
HBsAg, adw subtype, recombinant	8HS7-2ad	>98%	Recombinant

Other infectious diseases

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Human papillomavirus (HPV), type 16, oncoprotein E7	3HP16	716-325	IgG2a	EIA, WB
		716-332cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 18
		716-D1cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 18
Human papillomavirus (HPV), type 18, oncoprotein E7	3HP18	718-15cc	IgG1	*In vitro*, EIA, WB, C/r with HPV type 16
		718-67cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 16
Mycobacterium tuberculosis CFP10	3CFP1	KFB16	IgG1	EIA
		KFB42	IgG2b	EIA
Toxoplasma gondii	3Tx19	TP3cc	IgG2a	*In vitro*, EIA, WB, IF, P30 antigen

ANTIGENS

Product name	Cat. #	Purity	Source
Human papillomavirus L1 protein (HPVL1), type 16, recombinant	8HPV16	>90%	Recombinant
Human papillomavirus L1 protein (HPVL1), type 18, recombinant	8HPV18	>90%	Recombinant

Inflammation

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Calcitonin	4C10cc	P138	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		P139	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		P141	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		RC16B5	IgG1	CLIA, LF, a.a.r. 72-81 of PCT, recombinant chimeric antibody
		13G11cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		14A2cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		16B5cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		24B2cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
	4C10	13B9	IgG2a	EIA, a.a.r. 60-69 of PCT
		13F2	IgG1	EIA, WB, a.a.r. 72-81 of PCT
CD56	6L56	LT56cc	IgG2a	FC
C-reactive protein (CRP)	4C28cc	C2cc	IgG1	*In vitro*, EIA, high sensitivity
		C4cc	IgG1	*In vitro*, EIA, Ca^{2+} dependent, high sensitivity
		C6cc	IgG2a	*In vitro*, EIA, high sensitivity
		CRP30cc	IgG1	*In vitro*, EIA, low affinity
		CRP135cc	IgG2b	*In vitro*, EIA, high sensitivity
	4C28	C1	IgG2b	EIA, WB, high sensitivity
		C3	IgG1	EIA, IHC, Ca^{2+} dependent, high sensitivity
		C5	IgG1	EIA, high sensitivity
		C7	IgG1	EIA, IHC, high sensitivity
		CRP11	IgG1	EIA, WB
		CRP36	IgG2a	EIA, WB, IHC
		CRP169	IgG2a	EIA, WB
Interferon gamma	4I22	GC8cc	IgG1	*In vitro*, EIA, WB
		GF1cc	IgG1	*In vitro*, EIA, WB
		H3-1	IgG1	EIA, WB
Interleukin-1, beta	4IL12	11E5	IgG1	EIA, IHC
Interleukin-6	4IL6	L106	IgG1	*In vitro*, EIA, LF
		L137	IgG2a	*In vitro*, EIA, LF
		L143	IgG1	*In vitro*, EIA, LF
		L152	IgG1	*In vitro*, EIA, LF
		L395	IgG	EIA, LF, recombinant rabbbit antibody
		L519	IgG1	EIA, recombinant chimeric antibody
Myeloperoxidase (MPO)	4M43	4A4	IgG2b	EIA, WB
		18B7	IgG1	EIA, WB
		4B3	IgG1	EIA
		16E3	IgG1	EIA
		17G2	IgG2b	EIA
		19G8	IgG1	EIA
Procalcitonin (PCT)	4PC47	44D9	IgG2a	EIA, WB
		P123	IgG1	*In vitro*, EIA, a.a.r. 11-25 of PCT
		P124	IgG1	*In vitro*, EIA, a.a.r. 11-25 of PCT
		P135	IgG2a	*In vitro*, EIA, a.a.r. 11-25 of PCT
		P223	IgG1	CLIA, a.a.r. 11-25 of PCT, recombinant chimeric antibody
		6F10	IgG1	EIA, WB, a.a.r. 21-40 of PCT
		27A3cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 21-40 of PCT

Inflammation

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Procalcitonin (PCT)	4PC47	38F11	IgG1	EIA, WB, a.a.r. 21-40 of PCT
		42cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 21-40 of PCT
		P413	IgG2a	*In vitro*, CLIA, a.a.r. 96-105 of PCT, rat-mouse heterohybridoma antibody
		22A11	IgG1	EIA, WB, a.a.r. 96-105 of PCT
		P160	IgG1	*In vitro*, EIA, a.a.r. 102-108 of PCT
		14C12cc	IgG1	*In vitro*, EIA, WB, a.a.r. 102-111 of PCT
		18B7	IgG1	EIA, WB, a.a.r. 102-111 of PCT
Serum amyloid A (SAA)	4SA11	A491	IgG2b	EIA, rat monoclonal antibody
		A496	IgG1	EIA, rat monoclonal antibody
		SAA1cc	IgG1	*In vitro*, EIA, WB
		SAA6	IgG1	EIA, WB
		SAA15cc	IgG1	*In vitro*, EIA, WB
		VSA6	IgG1	EIA, WB
		VSA25	IgG1	EIA, WB
Serum amyloid A (SAA), animal	4VS4	VSA31cc	IgG2a	*In vitro*, EIA, WB, reacts also with human SAA
		VSA38cc	IgG2a	*In vitro*, EIA, WB, reacts also with human SAA
Tumor necrosis factor (TNF), alpha	4T10	F6C5cc	IgG1	*In vitro*, EIA, IHC
		2C8cc	IgG1	*In vitro*, EIA, IHC

POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Procalcitonin (PCT)	PPC3	goat	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
C-reactive protein (CRP), human, recombinant	8CR8	>95%	Recombinant
Interleukin 6 (IL-6), recombinant	8IL6	>90%	Recombinant
Procalcitonin (PCT), tag-free, recombinant	8PC5	>95%	Recombinant
Serum amyloid A1 (SAA1), human, recombinant	8SA1	>95%	Recombinant
Serum amyloid A2 (SAA2), human, recombinant	8SA2	>95%	Recombinant

DEPLETED SERUM

Product name	Cat. #	Source
C-reactive protein (CRP) free serum	8CFS	Pooled normal human serum
Myeloperoxidase free serum	8MPFS	Pooled normal human serum

Neuroscience

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Beta-amyloid, human	4BA3	BAM7cc	IgG1	*In vitro*, EIA
		BAM113cc	IgG1	*In vitro*, EIA
		BAM120cc	IgG1	*In vitro*, EIA
Glial fibrillary acidic protein (GFAP)	4G25	GFAP15cc	IgG1	*In vitro*, EIA, WB, IHC
		GFAP81cc	IgG1	*In vitro*, EIA, WB, IHC
		GFAP83cc	IgG1	*In vitro*, EIA, WB, IHC
		GFAP94cc	IgG1	*In vitro*, EIA, WB
		GFAP98cc	IgG1	*In vitro*, EIA, WB
Neurofilament light (NfL), human	4NF3	NF31	IgG2b	*In vitro*, EIA
		NF71	IgG2b	*In vitro*, EIA
		NF79	IgG2b	EIA, rat monoclonal antibody
		NF36	IgG	EIA, recombinant rabbit antibody
Neuron-specific enolase (NSE)	4N6	5G10	IgG2b	EIA, WB, IHC
		5E2	IgG2a	EIA, WB, IHC
		1C1	IgG2a	EIA
		H11	IgG2a	EIA
S100 proteins, human	4S37	8B10cc	IgG1	*In vitro*, EIA, WB, S100A1B and S100BB
		6G1cc	IgG1	*In vitro*, EIA, WB, S100A1B and S100BB
		3B10	IgG2a	EIA, WB, S100BB
		4B3	IgG2a	WB, S100A1B and S100BB

ANTIGENS

Product name	Cat. #	Purity	Source	
Calmodulin, bovine	8C10b	>95%	Bovine brain	
Calmodulin, human	8C10h	>95%	Human brain	
Glial fibrillary acidic protein (GFAP), human, recombinant	8G47	>90%	Recombinant	**New!**
Myelin basic protein (MBP)	8M79	>95%	Human brain	
Neuron-specific enolase (NSE)	8NS3	>95%	Human brain	
S100BB homodimer and S100A1B heterodimer, human	8S9h	>95%	Human brain	
S100BB homodimer and S100A1B heterodimer, bovine	8S9b	>95%	Bovine brain	
S100BB homodimer, human	8S9-2h	>95%	Human brain	
S100BB homodimer, bovine	8S9-2b	>95%	Bovine brain	

Tumor Markers

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks	
Alpha-fetoprotein (AFP)	4F16	5H7cc	IgG1	*In vitro*, EIA, WB	
		4A3cc	IgG1	*In vitro*, EIA, WB	
CA-125	4C29	RX16	IgG1	EIA, WB, A1 epitope group, recombinant antibody	New!
		X306cc	IgG1	*In vitro*, EIA, WB, A1 epitope group	
		X52cc	IgG1	*In vitro*, EIA, B2 epitope group	
		X75	IgG1	EIA, WB, B1 epitope group	
		X325	IgG1	EIA, WB, IHC, B1 epitope group	
CA19-9	4CA19	X91	IgM	EIA, IHC	
CA72-4	4CA72	7C1cc	IgG1	*In vitro*, EIA, WB	
		1C2cc	IgG1	*In vitro*, EIA, WB	
Carcinoembryonic antigen (CEA)	4CA30cc	3C8cc	IgG1	*In vitro*, WB, epitope group V	
		3C6cc	IgG1	*In vitro*, EIA, WB, IHC, epitope group I	
		3C10cc	IgG1	*In vitro*, WB, epitope group V	New!
	4CA30	3C1	IgG1	EIA, WB, epitope group IVa or II	
CYFRA21-1	4CY1	1X5cc	IgG1	*In vitro*, EIA	New!
		XC42cc	IgG1	*In vitro*, EIA, WB	
		1X3cc	IgG1	EIA, WB	
Human chorionic gonadotropin (HCG)	2H8	77F12	IgG2b	EIA, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH	
		F1cc	IgG1	*In vitro*, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH	
		27E8	IgG1	EIA, β-subunit, N/cr with LH, FSH, TSH	
		28A4	IgG2a	EIA, β-subunit, N/cr with LH, FSH, TSH	
Human epididymis protein 4 (HE4)	4HE6	2B13	IgG1	EIA	
		9D42	IgG1	EIA	
		3C24	IgG1	EIA	
Human papillomavirus (HPV), type 16, oncoprotein E7	3HP16	716-325	IgG2a	EIA, WB	
		716-332cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 18	
		716-D1cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 18	
Human papillomavirus (HPV), type 18, oncoprotein E7	3HP18	718-15cc	IgG1	*In vitro*, EIA, WB, C/r with HPV type 16	
		718-67cc	IgG2a	*In vitro*, EIA, WB, C/r with HPV type 16	
Kappa light chains	1K5cc	4G7cc	IgG2a	*In vitro*, EIA, WB, κ-chain purification by A/C, free and bound κ-chain	
Lambda (free) light chains	1L7cc	3D12cc	IgG2a	*In vitro*, EIA, WB, λ-chain purification by A/C, free λ-chain only	
Neuron-specific enolase (NSE)	4N6	5G10	IgG2b	EIA, WB, IHC	
		5E2	IgG2a	EIA, WB, IHC	
		1C1	IgG2a	EIA	
		H11	IgG2a	EIA	
Prostate-specific antigen (PSA)	4P33	8A6cc	IgG2a	*In vitro*, EIA, WB, free PSA, epitope 1	
		PS2	IgG1	EIA, equimolar total PSA, epitope 3, C/r with HK2	
		1H12cc	IgG1	*In vitro*, EIA, total PSA, epitope 4	
		5A6cc	IgG1	*In vitro*, EIA, WB, equimolar total PSA, epitope 5	

Tumor Markers

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
S100 proteins, human	4S37	8B10cc	IgG1	*In vitro*, EIA, WB, S100A1B and S100BB
		6G1cc	IgG1	*In vitro*, EIA, WB, S100A1B and S100BB
		3B10	IgG2a	EIA, WB, S100BB
		4B3	IgG2a	WB, S100A1B and S100BB
Thyroglobulin	2TG12cc	5E6cc	IgG2b	*In vitro*, EIA
		5F9cc	IgG2a	*In vitro*, EIA, IHC

ANTIGENS

Product name	Cat. #	Purity	Source
CA-125	8C29	N/A	Human adenocarcinoma
CA15-3	8CA15	N/A	Human milk, standard grade
CA19-9	8CA19	N/A	Human metastatic liver carcinoma
CA72-4	8CA72	N/A	Human metastatic liver carcinoma
Carcinoembryonic antigen (CEA)	8CEA88	N/A	Single patient source colon carcinoma liver metastatic tissue
Human papillomavirus L1 protein (HPVL1), type 16, recombinant	8HPV16	>90%	Recombinant
Human papillomavirus L1 protein (HPVL1), type 18, recombinant	8HPV18	>90%	Recombinant
Neuron-specific enolase (NSE)	8NS3	>95%	Human brain
S100BB homodimer and S100A1B heterodimer, human	8S9h	>95%	Human brain
S100BB homodimer and S100A1B heterodimer, bovine	8S9b	>95%	Bovine brain
S100BB homodimer, human	8S9-2h	>95%	Human brain
S100BB homodimer, bovine	8S9-2b	>95%	Bovine brain
Thyroglobulin	8TG52	>90%	Human thyroid gland
Thyroglobulin, human, recombinant	8RTG4	>95%	Recombinant

Bone Metabolism

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Osteocalcin, human	4OC8	2H9cc	IgG2a	*In vitro*, EIA
		6F9cc	IgG1	*In vitro*, EIA
		3G7	IgG2b	EIA
		1C4	IgG1	EIA
		1C7	IgG1	EIA
		3G8	IgG1	EIA
		8H12	IgG1	EIA

ANTIGEN

Product name	Cat. #	Purity	Source
A1-PINP, human, recombinant	8PIN7	>90%	Recombinant

Hormone Markers

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
17b-estradiol	2E2	ESTR-1	IgG1	EIA
Anti-Müllerian hormone (AMH), human	4AM5	AMH41cc	IgG2a	*In vitro*, EIA, WB
		AMH46cc	IgG2a	*In vitro*, EIA, WB
		AMH47cc	IgG2a	*In vitro*, EIA, WB
		AMH60cc	IgG2b	*In vitro*, EIA, WB
		AMH65cc	IgG1	*In vitro*, EIA, WB
		AMH69cc	IgG2b	*In vitro*, EIA, WB
Calcitonin	4C10cc	P138	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		P139	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		P141	IgG1	*In vitro*, CLIA, a.a.r. 72-81 of PCT
		RC16B5	IgG1	CLIA, LF, a.a.r. 72-81 of PCT, recombinant chimeric antibody
		13G11cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		14A2cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		16B5cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
		24B2cc	IgG1	*In vitro*, EIA, WB, a.a.r. 72-81 of PCT
	4C10	13B9	IgG2a	EIA, a.a.r. 60-69 of PCT
		13F2	IgG1	EIA, WB, a.a.r. 72-81 of PCT
Cortisol	2C2cc	XM210cc	IgG2a	*In vitro*, EIA, C/r data available
	2C2	CORT-1	IgG1	EIA, C/r data available
		CORT-2	IgG3	EIA, C/r data available
Follicle stimulating hormone (FSH), beta chain	2FSH2	F2	IgG1	EIA, WB
Growth hormone, human (hGH)	2G2	GhG2cc	IgG1	*In vitro*, EIA
		GhB9cc	IgG1	*In vitro*, EIA
Human chorionic gonadotropin (HCG)	2H8	77F12	IgG2b	EIA, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH
		F1cc	IgG1	*In vitro*, α-subunit, N/cr with β-subunit, C/r with LH, TSH, FSH
		27E8	IgG1	EIA, β-subunit, N/cr with LH, FSH, TSH
		28A4	IgG2a	EIA, β-subunit, N/cr with LH, FSH, TSH
Lactoferrin	4L2	2B8	IgG1	EIA, WB
		1A1	IgG1	EIA, WB
		1C6cc	IgG1	*In vitro*, EIA, WB
Luteinizing hormone (LH), beta chain	2LH2	L1	IgG1	EIA, WB
Progesterone	2P2	HPRO-2	IgG2b	EIA, C/r data available
		XM207	IgG2b	EIA, C/r data available
Prolactin	2PL7	1B2	IgG2a	EIA
		4G1cc	IgG1	*In vitro*, EIA
		8C3cc	IgG1	*In vitro*, EIA
Testosterone, human	2T2	XM209	IgG2a	EIA
Thyroid stimulating hormone (TSH)	2TS11cc	7G12cc	IgG1	*In vitro*, EIA, whole molecule, N/cr with human LH, FSH, HCG
		11E4cc	IgG1	*In vitro*, EIA, β-subunit, N/cr with human LH, FSH, HCG
		10C7cc	IgG1	*In vitro*, EIA, whole molecule, N/cr with human LH, FSH, HCG
		1CT1cc	IgG1	*In vitro*, EIA, WB in non-reducing conditions, beta-subunit, N/cr with human LH, FSH, HCG
	2TS11	7CT8	IgG1	EIA, beta-subunit, N/cr with human LH, FSH, HCG

Hormone Markers

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Thyroxine, human (T4)	2T6	1H1cc	IgG2a	*In vitro*, EIA, RIA
		XM212cc	IgG2a	*In vitro*, EIA
Triiodothyronine (T3)	2T7	3A6cc	IgG1	*In vitro*, EIA, RIA

ANTIGEN

Product name	Cat. #	Purity	Source
Anti-Müllerian hormone (AMH), human, recombinant	8AM7	>90%	Recombinant

Thyroid Diseases

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Thyroglobulin	2TG12cc	5E6cc	IgG2b	*In vitro*, EIA
		5F9cc	IgG2a	*In vitro*, EIA, IHC
Thyroid peroxidase (TPO)	4TP15	6H7	IgG1	EIA
		TPO28	IgG1	EIA WB
		TPO34	IgG1	EIA, WB
		TPO35	IgG1	EIA
Thyroid stimulating hormone (TSH)	2TS11cc	7G12cc	IgG1	*In vitro*, EIA, whole molecule, N/cr with human LH, FSH, HCG
		11E4cc	IgG1	*In vitro*, EIA, β-subunit, N/cr with human LH, FSH, HCG
		10C7cc	IgG1	*In vitro*, EIA, whole molecule, N/cr with human LH, FSH, HCG
		1CT1cc	IgG1	*In vitro*, EIA, WB in non-reducing conditions, beta-subunit, N/cr with human LH, FSH, HCG
	2TS11	7CT8	IgG1	EIA, beta-subunit, N/cr with human LH, FSH, HCG
Thyroxine, human (T4)	2T6	1H1cc	IgG2a	*In vitro*, EIA, RIA
		XM212cc	IgG2a	*In vitro*, EIA
Triiodothyronine (T3)	2T7	3A6cc	IgG1	*In vitro*, EIA, RIA

ANTIGENS

Product name	Cat. #	Purity	Source
Thyroglobulin	8TG52	>90%	Human thyroid gland
Thyroglobulin, human, recombinant	8RTG4	>95%	Recombinant
Thyroid peroxidase (TPO), recombinant	8RTP0	>95%	Recombinant

Veterinary

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Adenovirus hexon	3AV13	8C4	IgG2a	EIA, ID, IHC
Bovine corona virus	3BCV1	5A4	IgG1	EIA, HIT
Canine C-reactive protein (cCRP)	4CC5	cCRP1cc	IgG1	*In vitro*, EIA
		cCRP3	IgG2b	EIA, WB
		cCRP11cc	IgG1	*In vitro*, EIA
		cCRP34cc	IgG1	*In vitro*, EIA
Canine distemper virus (CDV)	3CD10	8-1	IgG2a	EIA, PLA
		5-4	IgG2a	EIA, PLA
Canine parvovirus (CPV)	3PV16	5G7	IgG2a	EIA, WB, ID, HIT
		8H7	IgG2a	EIA, WB, ID, HIT
		2A10	IgG2a	EIA
		3G3	IgG2a	EIA
		3H6	IgG3	EIA
Infectious bronchitis virus (IBV)	3BN1	IB95	IgG2a	EIA, WB
Influenza A haemagglutinin H7	3HI7	InA331	IgG1	EIA
		InA334	IgG1	EIA
		InA414	IgG2b	EIA
Insulin/Proinsulin, rat-mouse	2IP10cc	D6C4cc	IgG1	*In vitro*, EIA, IHC
		D3E7cc	IgG1	*In vitro*, EIA, IHC
Newcastle disease virus (NDV)	3ND5	9F7	IgG1	EIA, WB, HIT, haemagglutinin-neuraminidase
		1C10	IgG2a	EIA, HIT, haemagglutinin-neuraminidase
		8H2	IgG2a	EIA, haemagglutinin-neuraminidase
		6H12	IgG2a	IF, IHC, ribonucleoprotein
NT-proBNP, canine	4CNT5	CaNT89	IgG1	EIA, a.a.r. 19-28
		CaNT90	IgG1	EIA, a.a.r. 35-48
		CaNT19	IgG1	EIA, a.a.r. 42-50
		CaNT46	IgG1	EIA, a.a.r. 42-50
		CaNT49	IgG1	EIA, a.a.r. 66-72
		CaNT53	IgG1	EIA, a.a.r. 64-80
Proinsulin, rat	2PR8	CCI-17	IgG1	EIA
Rabies virus	3R7	1C5cc	IgG2a	*In vitro*, EIA, IHC
		4G4	IgG2b	EIA, ribonucleoprotein
		4F1	IgG2b	EIA, VN, glycoproteid
Rotavirus A	3R10	3C10cc	IgG2a	*In vitro*, EIA, IHC, WB, P42 antigen

Veterinary

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Serum amyloid A (SAA), animal	4VS4	F501	IgG1	EIA, feline, recombinant chimeric antibody
		F529	IgG1	EIA, feline, recombinant chimeric antibody
		F550	IgG1	EIA, feline, recombinant chimeric antibody
		F571	IgG1	EIA, feline, recombinant chimeric antibody
		F173	IgG2a	*In vitro*, EIA, feline, canine, equine, human
		F227	IgG1	*In vitro*, EIA, feline, canine, equine, human
		F231	IgG1	*In vitro*, EIA, feline, canine, equine, human
		F240	IgG2a	*In vitro*, EIA, feline, canine, equine, human
		SAA19cc	IgG2a	*In vitro*, EIA, feline, canine, equine, human
		SAA21cc	IgG2b	*In vitro*, EIA, feline, canine, equine, human
		VSA31cc	IgG2a	*In vitro*, EIA, feline, canine, equine, human
		VSA34cc	IgG2b	*In vitro*, EIA, feline, canine, equine, human
		VSA38cc	IgG2a	*In vitro*, EIA, feline, canine, equine, human
		VSA2	IgG1	EIA, canine, equine, human
		VSA43	IgG2b	EIA, canine, equine, human
Serum amyloid A (SAA), human	4SA11	SAA1cc	IgG1	*In vitro*, EIA, WB
		SAA15cc	IgG1	*In vitro*, EIA, WB
		SAA6	IgG1	EIA, WB
		VSA6	IgG1	EIA, WB
		VSA25	IgG1	EIA, WB
Thyroid stimulating hormone (TSH)	2TS11cc	11E4cc	IgG1	*In vitro*, EIA, WB in non-reducing conditions, beta-subunit
		1CT1cc	IgG1	*In vitro*, EIA, WB in non-reducing conditions, beta-subunit
	2TS11	7CT8	IgG1	EIA, beta-subunit

POLYCLONAL ANTIBODY

Product name	Cat. #	Host Animal	Remarks
Canine C-reactive protein (cCRP)	PRP4	Goat	EIA

ANTIGENS

Product name	Cat. #	Purity	Source
Calmodulin, bovine	8C10b	>95%	Bovine brain
Canine parvovirus (CPV) VP2, recombinant	8CP2	>90%	Recombinant
C-reactive protein (cCRP), canine, recombinant	8CC5	>95%	Recombinant
NT-proBNP, canine, recombinant	8CNT9	>95%	Recombinant
S100BB homodimer and S100A1B heterodimer, bovine	8S9b	>95%	Bovine brain
S100BB homodimer, bovine	8S9-2b	>95%	Bovine brain
Serum amyloid A (SAA), canine, recombinant	8CS4	>95%	Recombinant
Serum amyloid A (SAA), equine, recombinant	8ES6	>95%	Recombinant
Serum amyloid A (SAA), feline, recombinant	8FS5	>95%	Recombinant
Serum amyloid A (SAA), feline, recombinant, non-tagged	8FT7	>95%	Recombinant
Thyroid stimulating hormone (TSH), canine, recombinant	8CTS5	>90%	Recombinant

Veterinary

OTHER MONOCLONAL ANTIBODIES CROSS-REACTING WITH ANIMAL PROTEINS

Product name	Cat. #	MAb	Isotype	Remarks
Cortisol	2C2cc	XM210cc	IgG2a	*In vitro*, EIA
	2C2	CORT-1	IgG1	EIA
		CORT-2	IgG3	EIA
Cystatin C	4CC1	Cyst11	IgG1	EIA, dog and cat serum
		Cyst13	IgG1	EIA, WB, horse serum
		Cyst16	IgG1	EIA, dog and cat serum
		Cyst20	IgG1	EIA, dog, cat and horse serum
		Cyst29	IgG2a	EIA, dog, cat and horse serum
GAPDH	5G4cc	6C5cc	IgG1	*In vitro*, EIA, WB, IF, IHC, IP, porcine, canine, rabbit, cat, rat, mouse
	5G4	4G5	IgG1	EIA, WB, IF, IHC, IP, bovine, porcine, goat, cat, rat, mouse
Progesterone	2P2	HPRO-2	IgG2b	EIA
		XM207	IgG2b	EIA
Retinol-binding protein 4 (RBP4)	4RB2	RB42	IgG1	EIA, WB
		RB45	IgG1	EIA, WB
		RB48	IgG1	EIA, WB
		RB55	IgG1	EIA, WB
Thyroxine, human (T4)	2T6	1H1cc	IgG2a	*In vitro*, EIA, RIA
		XM212cc	IgG2a	*In vitro*, EIA
Triiodothyronine (T3)	2T7	3A6cc	IgG1	*In vitro*, EIA, RIA
Troponin I cardiac	4T21cc	4C2cc	IgG2a	*In vitro*, EIA, WB, a.a.r. 23-29
		M155cc	IgG1	*In vitro*, EIA, WB, a.a.r. 26-35
		19C7cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 41-49
	4T21	10F4	IgG2a	EIA, WB, a.a.r. 34-37, bovine, porcine, goat, canine, rabbit, cat, rat, mouse
		247	IgG1	a.a.r. 65-74, only free cTnI, bovine, porcine, goat, canine, cat, rat, mouse
		C5	IgG2b	EIA, WB, a.a.r. 186-192, >50 % C/r with skeletal troponin I, bovine, porcine, goat, canine, rabbit, cat, rat, mouse
Troponin T cardiac	4T19cc	1F11cc	IgG2b	*In vitro*, EIA, WB, a.a.r. 145-164
	4T19	2F3	IgG2b	EIA, WB, a.a.r. 145-164, porcine, goat
		1A11	IgG2b	EIA, WB, a.a.r. 145-164, bovine, porcine, goat, mouse

Metabolic Syndrome

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks	
Adiponectin, human	2AN6	Adn23	IgG2a	WB	
		Adn27	IgG2a	EIA	
		Adn36	IgG2a	EIA	
		Adn63	IgG1	EIA, WB	
		Adn94	IgG1	EIA	
		Adn279	IgG1	EIA	
		Adn305cc	IgG1	*In vitro*, EIA	
C-peptide, rat	2I3	CC27	IgG1	EIA	
		CC34	IgG1	EIA	
		CII-11	IgG1	EIA	
		CII-29	IgG1	EIA	
		CII-55	IgG1	EIA	
Hemoglobin, human, $HbA1_0$	4HH0	Hb4	IgG1	EIA	
		Hb6	IgG1	EIA	
Hemoglobin, human, glycated, $HbA1_c$	4HA1	75C9	IgG1	EIA	
Insulin, human	2I1	RC3A6	IgG1	EIA, recombinant chimeric antibody	New!
		RC8E2	IgG1	EIA, recombinant chimeric antibody	New!
		D4B8cc	IgG1	*In vitro*, EIA, IHC	
		C7C9	IgG1	C-terminal pentapeptide of β-chain	
		7F8	IgG1	EIA	
Insulin/Proinsulin, rat-mouse	2IP10cc	D6C4cc	IgG1	*In vitro*, EIA, IHC	
		D3E7cc	IgG1	*In vitro*, EIA, IHC	
Leptin, human	2LE1	3G7	IgG1	EIA, WB	
		4F12	IgG1	EIA, WB	
Proinsulin, rat	2PR8	CCI-17	IgG1	EIA	

ANTIGEN

Product name	Cat. #	Purity	Source
Adiponectin, human	8AN7	>95%	Pooled human plasma

Immunology and Serology

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
IgA	1A1cc	3B7cc	IgG1	*In vitro*, EIA, PHA, Fc-region
		1H9cc	IgG2b	*In vitro*, EIA, Fc-region
IgE	1E4cc	4F4cc	IgG1	*In vitro*, EIA, IgE purification by A/C, ε-chain (Cε 3 domain)
		5D4cc	IgG2a	*In vitro*, EIA, IgE purification by A/C, ε-chain (Cε 2 domain)
		E411cc	IgG1	*In vitro*, EIA, IgE Fc-region
	1E4	XTE4	IgG1	EIA, WB, ε-chain
		4H10	IgG1	EIA
IgG	1G1cc	5A9cc	IgG2a	*In vitro*, WB, ID, Fc-region, Pan γ (Cγ 2 domain), N/cr with IgA, IgM
		3D3cc	IgG2a	*In vitro*, EIA, WB, ID, Fc-region, Pan γ (Cγ 3 domain), N/cr with IgA, IgM
IgG1	1G2cc	2C11cc	IgG1	*In vitro*, EIA, IHC, ID, γ-1 Fc-region, N c/r with IgG2, IgG3, IgG4
IgG2	1G5	52G1	IgG1	EIA, Fc-region specific, γ-2 epitope, N/cr with IgG1, IgG3, IgG4, IgA, IgM, IgE
IgG3	1G3cc	5G12cc	IgG1	*In vitro*, EIA, γ-3 hinge region, N/cr with IgG1, IgG2, IgG4, IgA, IgM
IgG4	1G4cc	5C7cc	IgG1	*In vitro*, EIA, WB, γ-4 Fc-region, N/cr with IgG1, IgG2, IgG3, IgA, IgM
IgM	1M3cc	2B9cc	IgG2b	*In vitro*, WB, EIA, FC, μ-chain, Fc-region
Kappa light chains	1K5cc	4G7cc	IgG2a	*In vitro*, EIA, WB, κ-chain purification by A/C, free and bound κ-chain
Lambda (free) light chains	1L7cc	3D12cc	IgG2a	*In vitro*, EIA, WB, λ-chain purification by A/C, free λ-chain only
Ovine IgG	5O2	9E2	IgG1	EIA, WB, C/r with all artiodactylis

Kidney Diseases

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Cystatin C	4CC1	Cyst10	IgG3	EIA
		Cyst11	IgG1	EIA
		Cyst13	IgG1	EIA, WB
		Cyst16	IgG1	EIA
		Cyst19cc	IgG1	*In vitro*, EIA, WB
		Cyst20	IgG1	EIA
		Cyst23	IgG1	EIA
		Cyst24cc	IgG1	*In vitro*, EIA
		Cyst28	IgG1	EIA
		Cyst29	IgG2a	EIA
Human serum albumin (HSA)	4T24cc	15C7cc	IgG2b	*In vitro*, EIA, WB
	4T24	1C8	IgG1	EIA, WB
		1A9	IgG2a	EIA, WB
		6B11	IgG2a	EIA, WB
		14E7	IgG2b	EIA, WB
		HSA11	IgG1	EIA, WB
		HSA20	IgG1	EIA, WB
Kidney injury molecule-1 (KIM-1)	4KM1	KIM70	IgG1	EIA, WB
		KIM75	IgG1	EIA, WB
Neutrophil gelatinase-associated lipocalin (NGAL)	4NG7	N308	IgG	EIA, WB, recombinant rabbit antibody
		N316	IgG	EIA, WB, recombinant rabbit antibody
		N417	IgG1	*In vitro*, EIA, WB
		N422	IgG1	*In vitro*, EIA
		N432	IgG1	*In vitro*, EIA
		N457	IgG1	*In vitro*, EIA
		N461	IgG1	*In vitro*, EIA
Retinol-binding protein 4 (RBP4)	4RB2	RB42	IgG1	EIA, WB
		RB45	IgG1	EIA, WB
		RB48	IgG1	EIA, WB
		RB55	IgG1	EIA, WB

ANTIGENS

Product name	Cat. #	Purity	Source
Cystatin C, human, recombinant	8CY5	>95%	Recombinant
Neutrophil gelatinase-associated lipocalin (NGAL), human, recombinant	8NL2	>90%	Recombinant
Retinol-binding protein 4 (RBP4) from human plasma, free form	8RF9	>95%	Pooled human plasma
Retinol-binding protein 4 (RBP4) from human plasma, complexed with prealbumin	8RP7	>70%	Pooled human plasma

DEPLETED SERUM

Product name	Cat. #	Source
Cystatin C free serum	8CCFS	Pooled normal human serum

Microbial and Plant Toxins

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Aflatoxin from *Aspergillus flavus*	3Af27	ATB	IgG1	EIA
Cholera toxin	2C4	3D11	IgG2b	EIA, B-subunit of cholera toxin
Diphtheria toxin	2DT13	3B6	IgG1	EIA, N/cr with free A- and B-subunits
Staphylococcus aureus enterotoxin B	2S4	S222	IgG1	EIA, N/cr with A, C, D and E enterotoxin
		S643	IgG1	EIA, N/cr with A, C, D and E enterotoxin
Tetanus toxin	2TE8	TetE3	IgG1	EIA, WB

Gangliosides

GANGLIOSIDES

Product name	Cat. #	Purity	Source
Asialoganglioside GM1, bovine	8G16-1b	>98%	Bovine brain MW 1263
Asialoganglioside GM1, human	8G16-1h	>98%	Human brain MW 1263
Asialoganglioside GM2, bovine	8G16-15b	>98%	Bovine brain MW 1103
Disialoganglioside GD1a, bovine	8G16-6b	>98%	Bovine brain MW 1827
Disialoganglioside GD1a, human	8G16-6h	>98%	Human brain MW 1811
Disialoganglioside GD1a-NAcGal, bovine	8G16-17b	>98%	Bovine brain MW 2030
Disialoganglioside GD1b, bovine	8G16-7b	>98%	Bovine brain MW 1827
Disialoganglioside GD1b, human	8G16-7h	>98%	Human brain MW 1811
Disialoganglioside GD2, bovine	8G16-8b	>98%	Bovine brain MW 1665
Disialoganglioside GD2, human	8G16-8h	>98%	Human brain MW 1649
Disialoganglioside GD3, bovine	8G16-9b	>98%	Bovine brain MW 1461
Disialoganglioside GD3, human	8G16-9h	>98%	Human brain MW 1438
Monosialoganglioside GM1, bovine	8G16-2b	>98%	Bovine brain MW 1545
Monosialoganglioside GM1, human	8G16-2h	>98%	Human brain MW 1537
Monosialoganglioside GM2, bovine	8G16-3b	>98%	Bovine brain MW 1383
Monosialoganglioside GM2, human	8G16-3h	>98%	Human brain MW 1375
Monosialoganglioside GM3, bovine	8G16-4b	>98%	Bovine brain MW 1179
Monosialoganglioside GM3, human	8G16-4h	>98%	Human brain MW 1171
Monosialoganglioside GM4, bovine	8G16-5b	>98%	Bovine brain MW 1017
Monosialoganglioside GM4, human	8G16-5h	>98%	Human brain MW 1009
Tetrasialoganglioside GQ1b, bovine	8G16-12b	>98%	Bovine brain MW 2391
Tetrasialoganglioside GQ1b, human	8G16-12h	>98%	Human brain MW 2359
Trisialoganglioside GT1a, bovine	8G16-11b	>98%	Bovine brain MW 2109
Trisialoganglioside GT1b, bovine	8G16-10b	>98%	Bovine brain MW 2109
Trisialoganglioside GT1b, human	8G16-10h	>98%	Human brain MW 2085

Miscellaneous

MONOCLONAL ANTIBODIES

Product name	Cat. #	MAb	Isotype	Remarks
Coxsackievirus B3	3CX3	PV25	IgG2a	EIA
Cyclosporin A	3C13	CSZ22	IgG1	EIA
Fibronectin, human	4FBN3	FND5	IgG2a	EIA, WB
FITC	5F3cc	2A3cc	IgG1	*In vitro*, EIA, IHC
FK 506 (Tacrolimus)	4FK42	FK1	IgM	EIA
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	5G4cc	6C5cc	IgG1	*In vitro*, EIA, WB, IF, IHC, IP, C/r data available (WB control)
	5G4	4G5	IgG1	EIA, WB, IF, IHC, IP
His_6-Tag	5H1	His17	IgG1	EIA, WB, IP
Horseradish peroxidase (HRP)	4P14cc	2H11cc	IgG2b	*In vitro*, EIA, IHC, detects all isoforms
Insulin-like growth factor binding protein 5 (IGFBP-5)	4LGB5	IBPF12	IgG1	EIA, WB
		IBPF87	IgG2a	EIA, WB
Legionella pneumophila LPS	3L15	2F10	IgG3	EIA, C/r data available
		5F4RC	IgG3	EIA
Streptavidin from *Streptomyces avidinii*	3ST10	S8C12cc	IgG1	*In vitro*, EIA, WB, IHC

ANTIGEN

Product name	Cat. #	Purity	Source
Insulin-like growth factor binding protein 5 (IGFBP-5), human, recombinant	8GEF5	>90%	Recombinant

Alphabetical Index

Articles

Selected articles published by Hytest R&D scientists. Continuous investment in scientific research forms a solid foundation for our product development.

2024

Riabkova NS, Kogan AE, Katrukha IA, et al. Influence of Anticoagulants on the Dissociation of Cardiac Troponin Complex in Blood Samples. Int J Mol Sci. 2024;25(16):8919.

Riabkova NS, et al. Interaction of heparin with human cardiac troponin complex and its influence on the immunodetection of troponins in human blood samples. Clin Chem. Lab. Med. (2024)

2023

Adasheva DA, et al. PAPP-A-Specific IGFBP-4 Proteolysis in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Biochemistry (Moscow) 8;24(9):8420.

Katrukha IA , et al. Fragmentation of human cardiac troponin T after acute myocardial infarction. Clin Chim Acta. 2023 1;542:117281.

2022

Li L , et al. Diagnostic utility of total NT-proBNP testing by immunoassay based on antibodies targeting glycosylation-free regions of NT-proBNP. Clin Chem Lab Med. 2022 2;61(3):485-493.

2021

Serebryanaya DV, , et al. IGFBP-4 Proteolysis by PAPP-A in a Primary Culture of Rat Neonatal Cardiomyocytes under Normal and Hypertrophic Conditions. Biochemistry (Mosc). 86(11):1395-1406.

Katrukha IA and Katrukha AG. Myocardial Injury and the Release of Troponins I and T in the Blood of Patients, Clin Chem. 2021 Jan 8;67(1):124-130.

2020

Semenov AG. In-Depth Analysis of Molecular Heterogeneity of Circulating N-Terminal pro-BNP: Does Detailed Characterization of Analyte Structure Really Matter for Its Diagnostic Use? Clin Chem. 2020 Sep 1;66(9):1131-1133.

Konev AA, et al. CT-IGFBP-4 as a Novel Prognostic Biomarker in Acute Heart Failure. ESC Heart Fail. 2020 Apr;7(2):434-444.

2019

Vylegzhanina AV, Kogan AE, Katrukha IA, Koshkina EV, Bereznikova AV, Filatov VL, Bloshchitsyna MN, Bogomolova AP, Katrukha AG. Full-Size and Partially Truncated Cardiac Troponin Complexes in the Blood of Patients with Acute Myocardial Infarction. Clin Chem. 2019 Jul;65(7):882-892.

Semenov AG and Katrukha AG. A View on the Interrelationship Between Obesity and Natriuretic Peptide Measurements: Can Dysregulation in pro–B-type Natriuretic Peptide Glycosylation Explain Decreased B-type Natriuretic Peptide Concentrations in Obese Heart Failure Patients? Clin Chem. 2019 Sep;65(9):1070-1072.

Feygina EE, Artemieva MM, Postnikov AB, Tamm NN, Bloshchitsyna MN, Medvedeva NA, Katrukha AG, Semenov AG. Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure. Clin Chem. 2019 Oct;65(10):1239-1247.

Feygina EE, Katrukha AG, Semenov AG. Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang. Biochemistry (Mosc). 2019 Nov;84(11):1346-1358.

2018

Semenov AG and Feygina EE. Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. Adv. Clin. Chem. 2018;85:1-30.

Katrukha IA, Kogan AE, Vylegzhanina AV, Kharitonov AV, Tamm NN, Filatov VL, Bereznikova AV, Koshkina EV, Katrukha AG. Full-Size Cardiac Troponin I and Its Proteolytic Fragments in Blood of Patients with Acute Myocardial Infarction: Antibody Selection for Assay Development. Clin Chem. 2018 Jul;64(7):1104-1112.

Konev AA, Serebryanaya DV, Koshkina EV, Rozov FN, Filatov VL, Kozlovsky SV, Kara AN, Katrukha AG, Postnikov AB. Glycosylated and non-glycosylated NT-IGFBP-4 in circulation of acute coronary syndrome patients. Clin Biochem. 2018 May;55:56-62.

2017

Katrukha IA, Kogan AE, Vylegzhanina AV, Serebryakova MV, Koshkina EV, Bereznikova AV, Katrukha AG. Thrombin-Mediated Degradation of Human Cardiac Troponin T. Clin Chem. 2017 Jun;63(6):1094-1100.

Semenov AG, Tamm NN, Apple FS, Schulz KM, Love SA, Ler R, Feygina EE, Katrukha AG. Searching for a BNP standard: Glycosylated proBNP as a common calibrator enables improved comparability of commercial BNP immunoassays. Clin Biochem. 2017 Mar;50(4-5):181-185.

Vylegzhanina AV, Kogan AE, Katrukha IA, Antipova OV, Kara AN, Bereznikova AV, Koshkina EV, Katrukha AG. Anti-Cardiac Troponin Autoantibodies Are Specific to the Conformational Epitopes Formed by Cardiac Troponin I and Troponin T in the Ternary Troponin Complex. Clin Chem. 2017 Jan;63(1):343-350.

2016

Semenov AG, Katrukha AG. Analytical Issues with Natriuretic Peptides – has this been Overly Simplified? EJIFCC. 2016 Aug 1;27(3):189-207.

Semenov AG, Katrukha AG. Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter. Clin Chem. 2016 Apr;62(4):617-622.

Kogan AE, Mukharyamova KS, Bereznikova AV, Filatov VL, Koshkina EV, Bloshchitsyna MN, Katrukha AG. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul Fibrinolysis. 2016 Jul;27(5):542-550.

2015

Konev AA, Smolyanova TI, Kharitonov AV, Serebryanaya DV, Kozlovsky SV, Kara AN, Feygina EE, Katrukha AG, Postnikov AB. Characterization of endogenously circulating IGFBP-4 fragments-Novel biomarkers for cardiac risk assessment. Clin Biochem. 2015 Aug;48(12):774-780.

Kogan AE, et al. (2015) Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagul. Fibrinolysis, 2015 Dec 11. [Epub ahead of print] PubMed PMID: 26656897.

2014

Schulz O, Postnikov AB, Smolyanova TI, Katrukha AG, Schimke I, Jaffe AS. Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. Clin Biochem. 2014 Feb;47(3):177-183.

2013

Vylegzhanina AV, Katrukha IA, Kogan AE, Bereznikova AV. Epitope specificity of anti-cardiac troponin I monoclonal antibody 8I-7. Clin Chem. 2013 Dec;59(12):1814-1816.

Kogan AE, Filatov VL, Kolosova OV, Katrukha IA, Mironova EV, Zhuravleva NS, Nagibin OA, Kara AN, Bereznikova AV, Katrukha AG. Oligomeric adiponectin forms and their complexes in the blood of healthy donors and patients with type 2 diabetes mellitus. J Immunoassay Immunochem. 2013;34(2):180-196.

2012

Røsjø H, Tamm NN, Kravdal G, Seferian KR, Høiseth AD, Nygård S, Badr P, Røysland R, Omland T. Diagnostic utility of a single-epitope sandwich B-type natriuretic peptide assay in stable coronary artery disease: data from the Akershus Cardiac Examination (ACE) 1 Study. Clin Biochem. 2012 Nov;45(16-17):1269-1275.

Postnikov AB, Smolyanova TI, Kharitonov AV, Serebryanaya DV, Kozlovsky SV, Tryshina YA, Malanicev RV, Arutyunov AG, Murakami MM, Apple FS, Katrukha AG. N-terminal and C-terminal fragments of IGFBP-4 as novel biomarkers for short-term risk assessment of major adverse cardiac events in patients presenting with ischemia. Clin Biochem. 2012 May;45(7-8):519-524.

2011

Semenov AG, Seferian KR. Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing. Clin Chim Acta. 2011 May 12;412(11-12):850-860.

Semenov AG, Seferian KR, Tamm NN, Artem'eva MM, Postnikov AB, Bereznikova AV, Kara AN, Medvedeva NA, Katrukha AG. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem. 2011 Jun;57(6):883-890.

Tamm NN, Semenov AG, Seferian KR, Bereznikova AV, Murakami MM, Apple FS, Koshkina EV, Krasnoselsky MI, Katrukha AG. Measurement of B-type natriuretic peptide by two assays utilizing antibodies with different epitope specificity. Clin Biochem. 2011 Feb;44(2-3):257-259.

2010

Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010 Jul;56(7):1166-1176.

2009

Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, Bloshchitsyna MN, Koshkina EV, Krasnoselsky MI, Serebryanaya DV, Katrukha AG. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009 Mar;55(3):489-498.

2008

Tamm NN, Seferian KR, Semenov AG, Mukharyamova KS, Koshkina EV, Krasnoselsky MI, Postnikov AB, Serebryanaya DV, Apple FS, Murakami MM, Katrukha AG. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clin Chem. 2008 Sep;54(9):1511-1518.

Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, Postnikov AB, Serebryanaya DV, Apple FS, Murakami MM, Katrukha AG. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem. 2008 May;54(5):866-873.

2007

Kogan AE, Filatov VL, Kara AN, Levina AA, Katrukha AG. Comparison of soluble and placental transferrin receptors as standards for the determination of soluble transferrin receptor in humans. Int J Lab Hematol. 2007 Oct;29(5):335-340.

Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem. 2007 May;53(5):866-873.

2005

Kogan A, Filatov V, Gusev N, Bereznikova A, Kolosova O, Katrukha A. Immunological study of complex formation between soluble transferrin receptor and transferrin. Am J Hematol. 2005 Aug;79(4):281-287.

2003

Katrukha AG. Antibody selection strategies in cardiac troponin assays. Cardiac Markers, 2nd edition, Edited by Alan HB. Wu. 2003, 173-185.

1999

Katrukha A, Bereznikova A, Filatov V, Esakova T. Biochemical factors influencing measurement of cardiac troponin I in serum. Clin Chem Lab Med. 1999 Nov-Dec;37(11-12):1091-1095. Review.

Filatov VL, Katrukha AG, Bulargina TV, Gusev NB. Troponin: structure, properties, and mechanism of functioning. Biochemistry (Mosc). 1999 Sep;64(9):969-985. Review.

Katrukha A, Bereznikova A, Pettersson K. New approach to standardisation of human cardiac troponin I (cTnI). Scand J Clin Lab Invest Suppl. 1999;230:124-127.

1998

Katrukha AG, Bereznikova AV, Filatov VL, Esakova TV, Kolosova OV, Pettersson K, Lövgren T, Bulargina TV, Trifonov IR, Gratsiansky NA, Pulkki K, Voipio-Pulkki LM, Gusev NB. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem. 1998 Dec;44(12):2433-2440.

Filatov VL, Katrukha AG, Bereznikova AV, Esakova TV, Bulargina TV, Kolosova OV, Severin ES, Gusev NB. Epitope mapping of anti-troponin I monoclonal antibodies. Biochem Mol Biol Int. 1998 Sep;45(6):1179-1187.

1997

Katrukha AG, Bereznikova AV, Esakova TV, Pettersson K, Lövgren T, Severina ME, Pulkki K, Vuopio-Pulkki LM, Gusev NB. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem. 1997 Aug;43(8 Pt 1):1379-1385.

1995

Katrukha AG, Bereznikova AV, Esakova TV, Filatov VL, Bulargina TV, Gusev NB. A new method of human cardiac troponin I and troponin T purification. Biochem Mol Biol Int. 1995 May;36(1):195-202.

General Terms of Delivery

1. SCOPE OF APPLICATION

1.1 These General Terms and Conditions (the "General Terms and Conditions") shall apply to all sales of products by Hytest Ltd ("Hytest") to its client (the "Buyer"). Deviations from these General Terms and Conditions shall not apply unless otherwise agreed in writing.

1.2 If a separate supply agreement has not been concluded between the parties, these General Terms and Conditions together with Hytest's offer, the Buyer's unreserved order and Hytest's order confirmation shall form an agreement concerning delivery of products (the "Agreement"). By a reference these General Terms and Conditions form a part of a separate contract between Hytest and the Buyer.

1.3 These General Terms and Conditions shall enter into force on March 19, 2024 and shall be valid until further notice.

2. ORDERING, TERMS OF DELIVERY AND INSPECTION

2.1 The Buyer shall submit orders by electronic online service, electronic mail, or any other manner to the agreed point of contact. Order means a document or other similar request (in whatever mutually agreed technical form), issued by the Buyer where the Buyer requests Hytest to provide its products.

2.2 The products, as well as the prices, specifications, quantities, delivery times and other relevant issues related to the products shall be defined in each Agreement. The product shall fulfil the requirements and specifications set forth in the Agreement and comply with the applicable laws and regulations of the European Union and Finland at the time of delivery. Hytest makes no warranties, express or implied, and expressly disclaims any warranties and conditions regarding the products fitness for a particular purpose or end-use.

2.3 Unless otherwise specifically agreed in writing, the term of delivery for the products shall be FCA (Incoterms 2020), Turku, Finland. All shipments shall be via Federal Express or other similar courier, arranged by Hytest, all charges paid by the Buyer.

2.4 Time of delivery of the product set forth in the Agreement is estimate. Hytest's sole responsibility is to use reasonable commercial efforts to meet specified delivery dates. Hytest aims to promptly inform the Buyer in writing of any expected delay of the delivery, and effects thereof as well as the estimated new delivery time, if possible. Hytest shall not be liable for any loss or damage incurred by the Buyer due to Hytest's failure to meet the delivery times and the delivery shall not be considered delayed if the product cannot be timely shipped through no fault of Hytest. The Buyer shall not have the right to reschedule, cancel or otherwise amend submitted orders.

2.5 The Buyer shall perform an inspection and quality control of each shipment without delay and latest within fourteen (14) days from the date of the delivery. The Buyer shall during the time period reserved for the inspection and quality control inform Hytest in writing of all defects, errors and deficiencies ("Defects") detected or which should have been detected in the delivery and shall identify such Defects in sufficient detail.

2.6 Defects, which do not substantially interfere with the use of the product, shall not prevent the acceptance of the delivery.

2.7 The delivery shall be deemed to be accepted, when (a) the time reserved for the inspection and quality control has elapsed; (b) the Buyer has accepted the delivery in writing;
(c) Hytest has demonstrated that it has corrected all Defects reported by the Buyer in writing which prevented earlier acceptance; or (d) the Buyer takes the delivery into production use, whichever occurs first. The acceptance criteria set forth above in this Section 2.7 shall not be applied to the extent a Defect in a partial delivery could not have reasonably been noticed prior to the acceptance testing of a later delivered part of the delivery. Once the later delivered part of the delivery has been delivered, the acceptance criteria and the time period reserved for the inspection and quality control set forth above in this Section 2.7 shall be applied to such delivery in whole.

2.8 Where any valid claim based on any Defect in the quality or condition of the products or their failure to meet specification set forth in the Agreement is duly notified to Hytest in accordance with these General Terms and Conditions, Hytest shall replace the defective products (or the part in question) free of charge

or in Hytest's sole discretion, refund to the Buyer the price of the defective products. Hytest shall have no further liability to the Buyer with respect to any Defect in the products.

2.9 This Section 2 states the entire liability and obligations of Hytest and the sole and exclusive remedy of the Buyer with respect to any alleged or actual Defect in the delivery.

3. TITLE, RISK OF LOSS AND INTELLECTUAL PROPERTY RIGHTS

3.1 The title to the acquired product shall pass to the Buyer upon payment of the purchase price in full to Hytest's designated bank account.

3.2 All risk of loss or damage to the product shall pass to the Buyer in accordance with the terms of delivery specified in Section 2.3.

3.3 Hytest or its licensors, where applicable, shall own all intellectual property rights used on or relating to the products and any other documents or information prepared or potentially disclosed by Hytest in connection with the products delivered hereunder, including any copyright, patent, trademark, design right, trade secret and any other intellectual property rights whether or not capable of registration. Should the Buyer in connection with the use of the products delivered hereunder make, discover or conceive changes or modifications to the products, all intellectual property rights to such modifications shall become property of and be vested with Hytest. The Buyer undertakes not to take any action, including use of the product, that infringes Hytest's intellectual property rights. The Buyer shall not modify, alter, translate, reverse engineer, decompile, disassemble or attempt to discover the chemical, scientific or other structure of the products or any derivatives thereof, or use the product in an application or environment for which it was not intended or not contemplated to, or to make the products available for third parties as such, unless otherwise authorized by Hytest in writing. The Buyer is expressly prohibited from using the products, or any parts, modifications or derivatives thereof, as a basis for filing a patent application, claiming a new invention, or seeking any form of patent protection, unless otherwise authorized by Hytest in writing. The Buyer shall ensure that any use of the products does not contribute to or support any patent application filed by the Buyer or any third party.

4. PRICES AND TERMS OF PAYMENT

4.1 Unless otherwise agreed in the Agreement, Hytest's price list effective on the date of order shall apply. The prices are in Euros, unless otherwise agreed by the parties in writing. Hytest is entitled to revise its prices at its sole discretion.

4.2 The fees and prices are exclusive of value added tax and any other taxes, duty of any kind, export/import costs and other levies or delivery costs, and such taxes and public charges shall be added to Hytest's invoice. If the Buyer shall be responsible for any taxes and charges which may be levied, assessed or imposed on the use or delivery of the products, the Buyer is not entitled to deduct these taxes and charges from the fees and prices payable to Hytest. Value added tax, withholding tax and other similar taxes and public charges payable are subject to any changes in taxes or other public charges.

4.3 Hytest shall invoice for the products upon delivery. The term of payment is thirty (30) days net from the date of the invoice. Interest on overdue payments shall be charged at sixteen (16) per cent per annum. The interest period shall run from the due date for payment until receipt of the full amount by Hytest whether before or after judgement. In addition to the interest on overdue payments, Hytest shall also be entitled to compensation for relevant recovery costs incurred by Hytest as a consequence of late payment.

4.4 Hytest may at its sole discretion require an advance payment from the Buyer if the Buyer is a new client of Hytest or if the Buyer has had any previous payment delays. Hytest may withhold delivery of the ordered product, if the Buyer fails to pay any amount due under the Agreement on the due date for payment. Without affecting any other rights that it may be entitled to, Hytest may give notice in writing to the Buyer terminating the Agreement immediately if the Buyer fails to pay any amount due under the Agreement on the due date for payment and remains in default not less than 90 days after being notified in writing to make such payment.

5. CONFIDENTIALITY

5.1 Each party shall keep in confidence all material and information received from the other party and marked as confidential or which should be understood to be confidential, and may not use such material or information for any other

purposes than those set forth in the Agreement and only to the extent necessitated by the Agreement and shall have the right to disclose the said material and information to its employees, subcontractors and/or advisors only on a need-to-know basis provided, however, that they are obligated to keep the material and information in confidence and may not use them for any other purpose than the purpose of the Agreement. Without prejudice to the generality of the aforesaid, each party agrees to protect the confidentiality of the information at least with the same care as it exercises in respect of its own confidential information and business secrets but no less than due care.

5.2 The confidentiality obligation shall, however, not be applied to material and information, (a) which is generally available or otherwise public;
(b) which the party has received from a third party without any obligation of confidentiality; (c) which was in the possession of the receiving party prior to receipt of the same from the other party without any obligation of confidentiality related thereto; (d) which a party has independently developed without using material or information received from the other party and/or (e) which a party is obliged to disclose pursuant to a law, decree or other order issued by the authorities or a judicial order.

5.3 Upon the termination, cancellation of expiry of the Agreement or when a party no longer needs the material or information in question for the purpose stated in the Agreement, each party shall promptly cease using confidential material and information received from the other party and, unless the parties separately agree on destruction of such material, return the material in question (including all copies thereof). Each party shall, however, be entitled to retain the copies required by applicable law or regulation.

5.4 The rights and responsibilities under this Section 5 shall survive the termination, cancellation or expiry of the Agreement.

6. FORCE MAJEURE

6.1 Neither party shall be liable for failures to fulfil its obligations under the Agreement caused by an event beyond his control, which he could not have reasonably taken into account at the time of the conclusion of the Agreement, and whose consequences he could not reasonably have avoided or overcome including but not limited to accident, explosion, fire, storm, earthquake,

flood, drought, the elements, strikes, lockouts, labour disputes, riots, sabotage, terrorist acts, civil war or revolution, war, failure or delay of transportation, the bankruptcy of any supplier, acts of governments and their agencies, and governmental or their agencies' laws, regulations, rules, orders and decrees, or other legislative, administrative or judicial mandates. Strike, lockout, boycott and other industrial action shall constitute a force majeure event also when the party concerned is the target or a party to such an action.

6.2 A force majeure event suffered by a subcontractor of a party shall also discharge such party from liability, if subcontracting from other source cannot be made without unreasonable costs or significant loss of time.

6.3 Either party shall without delay inform the other party of a force majeure event in writing. The party shall correspondingly inform the other party of the termination of the force majeure event.

7. COMPLIANCE AND DATA PROCESSING

7.1 The Buyer agrees and acknowledges that it shall comply fully with all applicable laws and regulations in the performances of the Agreement and shall refrain from taking any action that could result in liability for Hytest under any applicable law, including the Criminal Code of Finland 39/1889, the UK Bribery Act 2010, the OECD Anti-Bribery and anti-corruption laws, regulations or conventions.

7.2 The Buyer undertakes to comply with, and ensure its sub-contractors comply with, the United States Export Administration Regulations, United States Office of Foreign Asset Control Sanction Program and any other applicable European regulations concerning export control and economic sanction, and to establish a procedure and take all necessary measures to ensure that the products shall not, directly or indirectly, be provided to any destination or country or to any individual or entity or for any activity or end-use restricted or prohibited by such laws and regulations, unless properly authorized by the appropriate government authorities.

7.3 In case any personal data is processed under this Agreement, the terms set forth in the privacy policy available at www.hytest.fi shall be applicable to such processing activities.

8. PRODUCT LIABILITY

8.1 The Buyer shall be obliged to familiarize itself with the product literature and the technical and scientific documentation provided by Hytest and shall use the products in accordance with such literature and documentation. Hytest shall defend (at its own cost) the Buyer against damages finally awarded in actions against the Buyer and instituted by third parties under the applicable product liability legislation to the extent such awarded damages concern liability for defective products or negligence of Hytest in respect of damage to private property (other than the product itself) or death or personal injury and which awarded damages have arisen from a defect subsisting in a product at the time of its delivery to the Buyer.

8.2 Hytest will not be liable for any product or any part of a product that: (a) has been damaged in shipment for which Hytest is not responsible according to the applicable delivery term; (b) becomes defective as a result of an accident after delivery to the Buyer, carelessness, improper storage, handling or use, or continued use where the products are unsuitable or fail to provide expected performance levels; or (c) becomes defective as a result of normal wear and tear. Failure to comply with any of the conditions set forth herein shall be deemed a waiver by the Buyer of all claims in respect of such products.

8.3 Any use or operation of products that are suspected of being defective or not in conformity with the agreed specifications, even if the existence of such a defect or non-conformity has not been verified, is strictly prohibited.

8.4 This Section 8 states the entire liability and obligations of Hytest and the sole and exclusive remedy of the Buyer and its customers for any product liability claims.

9. DISCLAIMER OF WARRANTIES

To the fullest extent permitted by applicable law, unless otherwise set forth in these General Terms and Conditions, Hytest disclaims all promises, representations and warranties with respect to Agreement and the products, including without limitation implied warranties of merchantability, satisfactory quality and fitness for a particular purpose, even if Hytest has been advised of the possibility of such damages.

10. LIMITATIONS OF LIABILITY

10.1 Hytest's total liability to the Buyer shall not exceed fifteen (15) per cent of the price of the products subject to the claim.

10.2 Neither party shall be liable to the other party for any indirect, incidental, special, punitive or consequential loss or damage, including but not limited to loss of profits or revenue, loss of use, loss of customers, loss of goodwill, cost of capital or investment, damage caused due to decrease or interruption in production or turnover whether arising under these terms and conditions, tort, or any other theory of liability, or otherwise.

10.3 The limitations of liability set forth in this Section 10 shall not apply to damages caused by willful conduct or gross negligence or which damages cannot be limited due to mandatory applicable laws or the Buyer's liability under Section 3.3 or Section 5 (Confidentiality).

11. NOTICES

Any notice, demand or other communication under Agreement by either party shall be in writing and shall be given or made by courier, registered mail or email (with delivery receipt). Any notice or other communication shall be deemed to have been duly received: (i) if delivered by courier, on the date and at the time that the courier's delivery receipt is signed, (ii) if sent by registered mail, on the third business day after posting; or (iii) if sent by email upon the delivery receipt is received.

12. SUBCONTRACTORS

Each party shall have the right to subcontract its obligations under the Agreement. Each party shall ensure that his subcontractors shall comply with the confidentiality provisions specified in these General Terms and Conditions. Each party shall be liable for the work of its subcontractors as for its own.

13. ASSIGNMENT

Neither party may assign or transfer the rights or obligations created through the Agreement without the prior written consent of the other party. However, Hytest shall be entitled to assign without prior notice or approval the Agreement and its rights and obligations under this

Agreement to its affiliates and in connection with a transfer of business, sale of assets or other equivalent corporate transaction. to a company to whom Hytest's business or its part is transferred.

14. ENTIRE AGREEMENT AND SEVERABILITY

14.1 The Agreement constitutes the entire agreement between the parties and no amendment hereof shall be effective unless in writing and approved by authorized representatives of the parties.

14.2 Unless set forth in writing and signed by both Hytest and the Buyer, no conditions, usage of trade, course of dealing or performance, understanding or agreement purporting to modify, vary, explain or supplement the General Terms and Conditions and the Agreement shall be binding and no modification shall be effected by the acknowledgment or acceptance of purchase order or shipping instruction forms containing terms or conditions at variance with or in addition to the General Terms and Conditions and the Agreement. Any and all general terms of delivery of the Buyer are hereby explicitly excluded.

14.3 If any provision of the General Terms and Conditions is declared invalid or unenforceable, all other provisions of the General Terms and Conditions shall remain in full force and effect.

15. NO AGENCY

Nothing in these General Terms and Conditions shall be construed as creating a partnership, agency, joint venture or any legal entity between Hytest and the Buyer. Hytest is not acting as a representative or agent of any of the parties with respect to the products.

16. APPLICABLE LAW AND SETTLEMENT OF DISPUTES

16.1 These General Terms and Conditions and the Agreement shall be governed by the laws of Finland, excluding its choice of law provisions. The Vienna Convention on the International Sale of Goods is excluded.

16.2 Any controversy, claim, or dispute arising out of or relating to these General Terms and Conditions or the Agreement or the breach, termination or invalidity thereof shall be finally

and exclusively settled in arbitration in accordance with the Arbitration Rules of the Finland Chamber of Commerce. The place of arbitration shall be Helsinki, Finland. The language of arbitral shall be English. The award thereof shall be final and binding upon the parties.

16.3 Notwithstanding the above, the parties shall have the right to file a claim for outstanding receivables under these General Terms and Conditions at the district court of Hytest's domicile.

16.4 Nothing in these General Terms and Conditions shall limit the parties' rights to seek interim relief or to enforce an arbitral award in any court of law.

16.5 Arbitral proceedings in accordance with this Section 16 and any information emanating from such arbitral proceedings, including any arbitral award, shall be treated as confidential information in accordance with Section 5.

Hytest Ltd 03/2024

PRODUCT CATALOG 2025

Hytest

Scientific excellence for IVD

HYTEST LTD

Intelligate 1, 6th floor, Joukahaisenkatu 6, FI-20520 Turku, FINLAND

Tel. +358 2 512 0900 • E-mail: hytest@hytest.fi • **HYTEST.FI**

OUR BROCHURES

Product Catalog • Cardiac Markers • Veterinary • Infectious Disease

Inflammation • Metabolic Syndrome • Neuroscience • Thyroid Diseases